Drug Safety and Availability
Information for consumers and health professionals on new drug warnings and other safety information, drug label changes, and shortages of medically necessary drug products.
Download the Drug Shortages Mobile Application
Drug Safety Communications
- Comunicado de la FDA sobre la seguridad de los medicamentos La FDA evaluará el riesgo potencial de defectos congénitos del tubo neural ocasionados por el medicamento contra el HIV dolutegravir (Juluca, Tivicay, Triumeq)
- La FDA agrega un recuadro de advertencia para recalcar la dosis correcta de Ocaliva (ácido obeticólico) para pacientes con una enfermedad hepática crónica poco frecuente
- Risk of serious and potentially fatal blood disorder prompts FDA action on oral over-the-counter benzocaine products used for teething and mouth pain and prescription local anesthetics
Drug Recalls
- Prinston Pharmaceutical Inc Issues Voluntary Nationwide Recall of Valsartan and Valsartan HCTZ Tablets Due to Detection of a Trace Amount of Unexpected Impurity, N-Nitrosodimethylamine (NDMA) in The Products
- Teva Pharmaceuticals USA Issues Voluntary Nationwide Recall of Valsartan and Valsartan Hydrochlorothiazide Tablets
- Major Pharmaceuticals Issues Voluntary Nationwide Recall of Valsartan Due to The Potential Presence of a Probable Carcinogen (NDMA)
